研究单位：[1]Jiangsu HengRui Medicine Co., Ltd.[2]Beijing Anzhen Hospital [3]Gansu Provincial Hospital,Lanzhou, Gansu, China[4]Tongji Hospital,Wuhan, Hubei, China, 430030[5]The Second Xiangya Hospital of Central South University,Changsha, Hunan, China[6]The Third Xiangya Hospital of Central South University,Changsha, Hunan, China[7]Northern Jiangsu People's Hospital,Yangzhou, Jiangsu, China, 225001[8]Shengjing Hospital of China Medical University,Shenyang, Liaoning, China, 110004[9]The First Affiliated Hospital of College of Medicine, Zhejiang University,Hangzhou, Zhejiang, China[10]Taizhou Hospital,Taizhou, Zhejiang, China[11]Beijing ANZHEN Hospital,Beijing, China, 100029[12]China-Japan Friendship Hospital,Beijing, China, 100029[13]Xuan Wu Hospital affiliated to Capital Medical University,Beijing, China, 100053[14]Beijing Tongren hospital affiliated to Capital Medical University,Beijing, China
研究目的：
The aim of present study is to evaluate the efficacy and safety of Extended-Release Carvedilol Sulfate versus Sustained-release Metoprolol Succinate in Patients With Mild or Moderate Chronic Heart Failure.
